Health Care & Life Sciences » Pharmaceuticals | NanoViricides Inc.

NanoViricides Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
219.70
212.00
302.70
659.50
663.00
680.10
Gross Income
219.70
212.00
302.70
659.50
663.00
680.10
SG&A Expense
6,370.70
8,455.40
6,760.40
8,200.00
8,937.80
8,645.10
EBIT
6,590.40
-
7,063.10
8,859.50
9,600.70
9,325.20
Unusual Expense
1,249.30
1,443.20
8,529.00
541.90
1,363.80
1,205.80
Interest Expense
1,091.50
3,662.00
3,824.90
2,469.70
2,128.50
544.50
Pretax Income
8,875.70
13,601.60
2,198.20
10,724.60
10,304.50
8,563.50
Consolidated Net Income
8,875.70
13,601.60
2,198.20
10,724.60
10,304.50
8,563.50
Net Income
8,875.70
13,601.60
2,198.20
10,724.60
10,304.50
8,563.50
Net Income After Extraordinaries
8,875.70
13,601.60
2,198.20
10,724.60
10,304.50
8,563.50
Net Income Available to Common
8,875.70
13,601.60
2,198.20
10,724.60
10,304.50
8,563.50
EPS (Basic)
0.68
0.27
0.09
0.19
0.17
0.13
Basic Shares Outstanding
13,112.20
51,225.80
56,553.80
57,669.50
60,102.90
64,920.90
EPS (Diluted)
0.68
0.27
0.09
0.19
0.17
0.13
Diluted Shares Outstanding
13,112.20
51,225.80
59,220.50
57,669.50
60,102.90
64,920.90
EBITDA
6,370.70
8,455.40
6,760.40
8,200.00
8,937.80
8,645.10
Non-Operating Interest Income
55.60
171.00
160.90
62.60
61.00
100.40

About NanoViricides

View Profile
Address
1 Controls Drive
Shelton Connecticut 06484
United States
Employees -
Website http://www.nanoviricides.com
Updated 07/08/2019
NanoViricides, Inc. is a nano-biopharmaceutical company. The company engages in the discovery, development, and commercialization of therapeutics to advance the care of patients suffering from life-threatening viral infections. It intends to manufacture Injectable and Oral FluCide, HIVCide, Nanoviricide Eye Drops, HerpeCide, DengueCide, RabiCide as well as other drugs for pre-clinical animal studies and human clinical studies.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.